October 26th, 2009 – Avineuro Pharmaceuticals, Inc. reported clinical Phase I results on AVN-101, a potent small molecule for treatment of Alzheimer’s disease. AVN-101 was well tolerated in a wide range of doses and no adverse events were observed. Avineuro Pharmaceuticals, Inc. plans to start Phase II clinical trials with AVN-101 in Alzheimer’s disease in Q1 2010... Avineuro Pharmaceuticals' Press Release -
Showing posts with label Avineuro Pharmaceuticals. Show all posts
Showing posts with label Avineuro Pharmaceuticals. Show all posts
Tuesday, October 27, 2009
Avineuro : positive Phase I clinical trial results on AVN-101, potent small molecule for treatment of Alzheimer’s disease.
October 26th, 2009 – Avineuro Pharmaceuticals, Inc. reported clinical Phase I results on AVN-101, a potent small molecule for treatment of Alzheimer’s disease. AVN-101 was well tolerated in a wide range of doses and no adverse events were observed. Avineuro Pharmaceuticals, Inc. plans to start Phase II clinical trials with AVN-101 in Alzheimer’s disease in Q1 2010... Avineuro Pharmaceuticals' Press Release -
Subscribe to:
Posts (Atom)
